When should a hepatitis B (HBV) titer be done?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When to Perform Hepatitis B Titer Testing

Hepatitis B antibody (anti-HBs) testing should be performed 1–2 months after completing the primary vaccine series or after any booster dose to document immune response and guide future management. 1, 2

Routine Post-Vaccination Testing

After Primary Vaccination Series

  • Test anti-HBs levels 1–2 months after the final dose of the primary vaccine series to document protective immunity (≥10 mIU/mL) for future reference 1, 2
  • Use a quantitative assay (e.g., ELISA) that can detect the protective threshold of ≥10 mIU/mL 2
  • This timing applies universally across all populations completing the standard vaccination schedule 2

After Booster Doses

  • Recheck anti-HBs 1–2 months after any booster dose to assess immune response 2, 3
  • If a second complete vaccine series is administered (for non-responders), test 1–2 months after the final dose of that series 1

Special Circumstances Requiring Modified Timing

When HBIG Was Administered

  • Wait 4–6 months after HBIG administration before testing anti-HBs levels, as passively acquired antibodies from HBIG interfere with accurate assessment of vaccine-induced immunity 1, 2
  • Testing earlier will yield falsely elevated results that don't reflect true vaccine response 2

Healthcare Personnel After Occupational Exposure

  • Test immediately after exposure (baseline) if the healthcare worker has anti-HBs <10 mIU/mL or unknown vaccination status 1
  • Baseline testing should include total anti-HBc 1
  • Follow-up testing at 6 months should include HBsAg and total anti-HBc 1

High-Risk Populations Requiring Ongoing Surveillance

Hemodialysis Patients

  • Perform annual anti-HBs testing regardless of initial response 3, 4
  • Administer a booster dose when anti-HBs levels decline below 10 mIU/mL 3
  • These patients may lose naturally acquired immunity over time and require closer monitoring 4

Immunocompromised Individuals

  • Consider annual anti-HBs testing if ongoing risk for exposure exists 3
  • Administer boosters when levels fall below 10 mIU/mL 3, 5
  • This includes patients after liver transplantation who require regular serological monitoring 5

Healthcare Workers at Ongoing Risk

  • Test anti-HBs levels if vaccination history is undocumented or if post-vaccination testing was never performed 3, 6
  • For those with documented anti-HBs <10 mIU/mL, administer one booster dose and retest 1–2 months later 3
  • If still <10 mIU/mL after the booster, complete a second 3-dose series and retest 3

When Testing Is NOT Necessary

Immunocompetent Individuals with Documented Response

  • Do not perform routine periodic testing in healthy individuals who achieved anti-HBs ≥10 mIU/mL after primary vaccination 1, 5
  • Immune memory persists even when antibody levels decline below detectable levels 3, 5, 7
  • Long-term protection is maintained through cellular immune memory, not circulating antibody levels 3, 5

Unvaccinated or Incompletely Vaccinated Persons

  • Do not test anti-HBs in unvaccinated or incompletely vaccinated individuals, as the protective threshold of ≥10 mIU/mL has only been validated for those who completed an approved vaccination series 1
  • Testing in this population is potentially misleading 1

Common Pitfalls to Avoid

  • Testing too early (before 4 weeks) may underestimate peak antibody response and miss true immunity 2
  • Forgetting HBIG interference can yield falsely elevated results that don't reflect vaccine-induced immunity 1, 2
  • Using qualitative tests instead of quantitative assays prevents confirmation of the protective threshold 2
  • Administering unnecessary boosters to healthy immunocompetent individuals who completed the primary series wastes resources and is not evidence-based 3
  • Relying solely on antibody levels in immunocompetent individuals ignores the persistence of immune memory even when anti-HBs is undetectable 3, 5
  • Overlooking post-vaccination testing in high-risk groups (healthcare workers, hemodialysis patients, immunocompromised individuals) fails to document initial response for future management 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Timing of Post-Booster Hepatitis B Antibody Testing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hepatitis A and B Booster Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003

Research

Assessment of long-term efficacy of hepatitis B vaccine.

European journal of epidemiology, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.